Conference Correspondent

Can MDHAQ/RAPID3 Be Used in Usual Care of Patients with Systemic Lupus Erythematosus?

Conference Correspondent - Conference Correspondent

Disease-specific patient-reported outcome (PRO) tools would be useful in the management of a number of rheumatologic conditions, including rheumatoid arthritis (RA), psoriatic arthritis, and systemic lupus erythematosus (SLE). The challenge has been to incorporate validated disease-specific PRO measures into practical use in patient care. Ideally, the PRO tool would be one that could be easily integrated during the office or clinic check-in process that would not require input from healthcare personnel or additional administrative processes. The Multidimensional Health Assessment Questionnaire (MDHAQ) is such a PRO tool that has been successfully used for a number of rheumatologic conditions, including for RA. Similarly, the Routine Assessment of Patient Index Data (RAPID3) can be quickly calculated from the MDHAQ. To test the value of MDHAQ and RAPID3 in patients with SLE, Annapureddy and colleagues (Abstract 188) compared RAPID3 and LupusPRO, a  validated, disease-specific PRO tool for SLE, in patients with SLE who were seen during usual care.

A total of 78 patients with SLE completed both MDHAQ and LupusPRO during a routine office visit. At these visits, SLE disease activity was assessed using standard Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index and Physician’s Global Assessment scores. LupusPRO domain scores for 8 health-related quality-of-life (HRQOL) scales and 4 non-HRQOL scales were compared with RAPID3 scores that were stratified by 4 disease severity categories (ie, remission, low severity, medium severity, and high severity).

Of the 12 LupusPRO domains, 7 differed significantly in patients in the 4 RAPID3 disease severity categories, including lupus symptoms, cognition, physical health, pain/vitality, emotional health, body image, and desires/goals. Conversely, 5 of the 12 LupusPRO domains did not differ in the 4 RAPID3 disease severity categories, including procreation, lupus medications, social support, coping, and satisfaction with treatment. Moreover, the composite HRQOL LupusPRO scores differed significantly in the RAPID3 disease severity categories, although the composite non-HRQOL scores did not differ. It appears from these data that the RAPID3 correlates well with LupusPRO-HRQOL domains and can be used as a PRO tool for measuring HRQOL in patients with SLE in clinical settings and may add information that is of value in managing SLE in these patients. As RAPID3 is a generic tool, it may be easily integrated into busy clinical practices without overburdening clinic/office processes and resources.

Related Items
Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Improved Quality of Life in Adults with Acute Bacterial Skin and Skin Structure Infections with Omadacycline or Linezolid Therapy
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Omadacycline In Vitro Activity Against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Integrated Safety Summary of Omadacycline, A Novel Aminomethylcycline Antibiotic
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Last modified: February 14, 2019
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME